Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.
Authors
- Clementina López‐Medina (ORCID: https://orcid.org/0000-0002-2309-5837)
- Denis Poddubnyy (ORCID: https://orcid.org/0000-0002-4537-6015)
- Mindy Kim (ORCID: https://orcid.org/0000-0003-3133-0195)
- Sofía Ramiro (ORCID: https://orcid.org/0000-0002-8899-9087)
- Ute Massow
- V. Taieb (ORCID: https://orcid.org/0000-0003-0655-8630)
- Tue Wenzel Kragstrup (ORCID: https://orcid.org/0000-0002-6439-397X)
- Dennis McGonagle (ORCID: https://orcid.org/0000-0001-7715-8226)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
Institutions
- University Health Network (CA)
- Aarhus University (DK)
- Leeds Teaching Hospitals NHS Trust (GB)
- Leiden University Medical Center (NL)
- Aarhus University Hospital (DK)
- Swedish Medical Center (US)
- UCB Pharma (France) (FR)
- Regionshospitalet Silkeborg (DK)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Hospital Universitario Reina Sofía (ES)
- Zuyderland Medisch Centrum (NL)
- UCB Pharma (Germany) (DE)
- Cordoba University (US)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-005969
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00